2A+ Farma Portal de notícias
Clarity Pharma, a UK headquartered distribution partner to mid-market pharmaceutical companies around the world, has announced that a March 2021 audit saw Unit 1 of its warehousing infrastructure achieve Medical Healthcare Regulatory Agency (MHRA) licence approval. The accreditation is in compliance with the new Medical Device Regulations, which came into place in May 2020, and complements the company’s existing licence for its Unit 3 facility.
Capa » International News (Página 11)
International News
New daily COVID-19 cases could reach 1.4 million by end of May in India, according to GlobalData
India could reach approximately 1.4 million new daily COVID-19 cases by May 24, if current transmission risk is not reduced further, according to a two-week forecast by GlobalData, a leading data and analytics company.
Swedish Chordate Medical receives CE mark approval for neuromodulation treatment of Chronic Migraine
Chordate Medical Holding AB (publ) (“the company, or “Chordate”) is a Swedish medical technology company that has developed and patented an innovative treatment method: K.O.S. The company’s existing EC-certificate for K.O.S has now been granted an extension with the indication Chronic Migraine and the intended use: Preventive treatment of chronic migraine in adults over 18 years. The CE marking means that the K.O.S treatment meets the clinical efficacy and safety requirements for in the European Medical Devices Directive for the new indication. The approval allows Chordate to commercialize the migraine treatment within the EU. This CE marking comes one year ahead of the company’s preliminary plan.
Better access to dental care could help Brazil win battle against COPD
06 May 2021
Oral health in Brazil needs better promotion and more accessible public dental services, in order to help tackle the impact of Chronic Obstructive Pulmonary Disease (COPD) – the country’s third leading cause of adult death, according to a new study.
China’s fast-track regulatory reforms face difficulties in attracting non-Chinese companies, says GlobalData
China has reformed its regulatory system in recent years to include various fast-track programs similar to the US, EU, and Japan to incentivize the development of drugs for unmet medical needs and serious conditions. However, only a few companies based outside of China have been granted priority review status by the National Medical Products Administration (NMPA) for their drug applications, says GlobalData, a leading data and analytics company.
Marchesini Group closed 2019 with a consolidated turnover of 441 million Euro, a repeat of the performance in 2018
Marchesini Group closed 2019 with a consolidated turnover of 441 million Euro, a repeat of the excellent performance in 2018. Leia Mais »
Marchesini Group presents ‘X DAYS 2020’
Pianoro (Bologna) – Now, more than ever, we need some extraordinary events to keep in touch. In May, Marchesini Group should have welcomed its customers at its exhibition booth at the German trade show Interpack, where it should have illustrated the new technologies exploited to package pharmaceutical and cosmetic products. Leia Mais »
ASME announced that it will take steps to limit the spread of the coronavirus
By Rodolfo Cosentino. Leia Mais »
Interphex 2020: the Marchesini Group focuses on serialization and inspection machines
West Caldwell (New Jersey) – February 10th, 2020 – The Marchesini Group returns to the Jacob K. Javits Center in New York (April 28-30) for the 41th edition of Interphex, the premier pharmaceutical, biotechnology and device development and manufacturing event in the U.S.
Leia Mais »
Pharma companies seek hike in drug rates under price control
With a 50-200% rise in the cost of raw materials imported from China, pharmaceutical lobby groups have urged the government to invoke extraordinary powers to hike prices of drugs under price control, according to sources. Leia Mais »